Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.74)
# 3,669
Out of 4,765 analysts
110
Total ratings
22.77%
Success rate
-30.9%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Reiterates: Buy | $30 | $8.73 | +243.64% | 2 | Mar 12, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $30 | $13.50 | +122.22% | 6 | Mar 10, 2025 | |
| UBX Unity Biotechnology | Reiterates: Buy | $8 | $1.79 | +346.93% | 5 | Mar 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $4.22 | +563.51% | 8 | Mar 7, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $6.81 | +46.84% | 11 | Mar 3, 2025 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $4.28 | +741.12% | 18 | Mar 3, 2025 | |
| OPT Opthea | Reiterates: Buy | $12 | $3.07 | +290.88% | 6 | Feb 28, 2025 | |
| IMUX Immunic | Reiterates: Buy | $10 | $1.12 | +792.86% | 2 | Feb 21, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $0.93 | +760.22% | 2 | Feb 19, 2025 | |
| FBLG FibroBiologics | Reiterates: Buy | $12 | $1.01 | +1,088.12% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.62 | +23.46% | 15 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $11.89 | +169.04% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $18 | $5.37 | +235.20% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $4.50 | +566.67% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $3.45 | -13.04% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $5.67 | +23.46% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $24.75 | +53.54% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.18 | +1,042.86% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.73 | +15.61% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $223.66 | -87.48% | 1 | Aug 22, 2023 |
Zenas BioPharma
Mar 12, 2025
Reiterates: Buy
Price Target: $30
Current: $8.73
Upside: +243.64%
Mineralys Therapeutics
Mar 10, 2025
Reiterates: Buy
Price Target: $30
Current: $13.50
Upside: +122.22%
Unity Biotechnology
Mar 10, 2025
Reiterates: Buy
Price Target: $8
Current: $1.79
Upside: +346.93%
Phathom Pharmaceuticals
Mar 7, 2025
Reiterates: Buy
Price Target: $28
Current: $4.22
Upside: +563.51%
Aldeyra Therapeutics
Mar 3, 2025
Reiterates: Buy
Price Target: $10
Current: $6.81
Upside: +46.84%
4D Molecular Therapeutics
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $4.28
Upside: +741.12%
Opthea
Feb 28, 2025
Reiterates: Buy
Price Target: $12
Current: $3.07
Upside: +290.88%
Immunic
Feb 21, 2025
Reiterates: Buy
Price Target: $10
Current: $1.12
Upside: +792.86%
Opus Genetics
Feb 19, 2025
Reiterates: Buy
Price Target: $8
Current: $0.93
Upside: +760.22%
FibroBiologics
Feb 13, 2025
Reiterates: Buy
Price Target: $12
Current: $1.01
Upside: +1,088.12%
Feb 6, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.62
Upside: +23.46%
Jan 30, 2025
Initiates: Buy
Price Target: $32
Current: $11.89
Upside: +169.04%
Jan 3, 2025
Maintains: Buy
Price Target: $5 → $18
Current: $5.37
Upside: +235.20%
Nov 19, 2024
Reiterates: Buy
Price Target: $30
Current: $4.50
Upside: +566.67%
Nov 15, 2024
Reiterates: Neutral
Price Target: $3
Current: $3.45
Upside: -13.04%
Nov 15, 2024
Reiterates: Buy
Price Target: $7
Current: $5.67
Upside: +23.46%
Nov 7, 2024
Reiterates: Buy
Price Target: $38
Current: $24.75
Upside: +53.54%
Aug 15, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.18
Upside: +1,042.86%
Aug 12, 2024
Reiterates: Neutral
Price Target: $2
Current: $1.73
Upside: +15.61%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $223.66
Upside: -87.48%